Key result
Antithrombotic therapy outcomes in COVID-19 outpatients remain undetermined.
Answers are grounded in this paper and cite their sources.
Antithrombotic regimens do not reduce events in stable COVID outpatients; leaves open optimal prophylaxis strategies in higher-risk groups.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Otavio B Berwanger (2021) studied COVID-19. Antithrombotic Therapy was evaluated. Antithrombotic therapy outcomes in outpatients with COVID-19 could not be determined because the abstract text is missing.
Synapse has enriched 10 related papers. Consider them for comparative context: